These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
512 related articles for article (PubMed ID: 21398060)
1. FDG-PET-CT and whole-body MRI for triage in patients planned for radioembolisation therapy. Schmidt GP; Paprottka P; Jakobs TF; Hoffmann RT; Baur-Melnyk A; Haug A; Notohamiprodjo M; Baur-Melnyk A; Nikolaou K; Reiser MF; Rist C Eur J Radiol; 2012 Mar; 81(3):e269-76. PubMed ID: 21398060 [TBL] [Abstract][Full Text] [Related]
2. Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma. Balbo-Mussetto A; Cirillo S; Bruna R; Gueli A; Saviolo C; Petracchini M; Fornari A; Lario CV; Gottardi D; De Crescenzo A; Tarella C Clin Radiol; 2016 Mar; 71(3):271-9. PubMed ID: 26749081 [TBL] [Abstract][Full Text] [Related]
3. Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT. Schmidt GP; Baur-Melnyk A; Haug A; Heinemann V; Bauerfeind I; Reiser MF; Schoenberg SO Eur J Radiol; 2008 Jan; 65(1):47-58. PubMed ID: 18082989 [TBL] [Abstract][Full Text] [Related]
4. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer. Haug AR; Tiega Donfack BP; Trumm C; Zech CJ; Michl M; Laubender RP; Uebleis C; Bartenstein P; Heinemann V; Hacker M J Nucl Med; 2012 Mar; 53(3):371-7. PubMed ID: 22331219 [TBL] [Abstract][Full Text] [Related]
5. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI. Wong CY; Salem R; Raman S; Gates VL; Dworkin HJ Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):815-20. PubMed ID: 12029557 [TBL] [Abstract][Full Text] [Related]
6. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer. Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167 [TBL] [Abstract][Full Text] [Related]
7. Diagnostic accuracy of dynamic gadoxetic-acid-enhanced MRI and PET/CT compared in patients with liver metastases from neuroendocrine neoplasms. Armbruster M; Zech CJ; Sourbron S; Ceelen F; Auernhammer CJ; Rist C; Haug A; Singnurkar A; Reiser MF; Sommer WH J Magn Reson Imaging; 2014 Aug; 40(2):457-66. PubMed ID: 24347148 [TBL] [Abstract][Full Text] [Related]
8. Comparison of the utility of whole-body MRI with and without contrast-enhanced Quick 3D and double RF fat suppression techniques, conventional whole-body MRI, PET/CT and conventional examination for assessment of recurrence in NSCLC patients. Ohno Y; Nishio M; Koyama H; Yoshikawa T; Matsumoto S; Takenaka D; Seki S; Tsubakimoto M; Sugimura K Eur J Radiol; 2013 Nov; 82(11):2018-27. PubMed ID: 24012452 [TBL] [Abstract][Full Text] [Related]
13. Supplemental value of diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) technique to whole-body magnetic resonance imaging in detection of bone metastases from thyroid cancer. Sakurai Y; Kawai H; Iwano S; Ito S; Ogawa H; Naganawa S J Med Imaging Radiat Oncol; 2013 Jun; 57(3):297-305. PubMed ID: 23721138 [TBL] [Abstract][Full Text] [Related]
14. Whole-body MRI at 1.5 T and 3 T compared with FDG-PET-CT for the detection of tumour recurrence in patients with colorectal cancer. Schmidt GP; Baur-Melnyk A; Haug A; Utzschneider S; Becker CR; Tiling R; Reiser MF; Hermann KA Eur Radiol; 2009 Jun; 19(6):1366-78. PubMed ID: 19190917 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography. Armbruster M; Sourbron S; Haug A; Zech CJ; Ingrisch M; Auernhammer CJ; Nikolaou K; Paprottka PM; Rist C; Reiser MF; Sommer WH Invest Radiol; 2014 Jan; 49(1):7-14. PubMed ID: 24002080 [TBL] [Abstract][Full Text] [Related]
17. Angiography-based C-arm CT for the assessment of extrahepatic shunting before radioembolization. Heusner TA; Hamami ME; Ertle J; Hahn S; Poeppel T; Hilgard P; Bockisch A; Forsting M; Antoch G Rofo; 2010 Jul; 182(7):603-8. PubMed ID: 20183775 [TBL] [Abstract][Full Text] [Related]
18. SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer. Hamami ME; Poeppel TD; Müller S; Heusner T; Bockisch A; Hilgard P; Antoch G J Nucl Med; 2009 May; 50(5):688-92. PubMed ID: 19372479 [TBL] [Abstract][Full Text] [Related]
19. Computed tomography hepatic arteriography has a hepatic falciform artery detection rate that is much higher than that of digital subtraction angiography and 99mTc-MAA SPECT/CT: implications for planning 90Y radioembolization? Burgmans MC; Too CW; Kao YH; Goh AS; Chow PK; Tan BS; Tay KH; Lo RH Eur J Radiol; 2012 Dec; 81(12):3979-84. PubMed ID: 22954411 [TBL] [Abstract][Full Text] [Related]
20. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. Smits ML; Nijsen JF; van den Bosch MA; Lam MG; Vente MA; Mali WP; van Het Schip AD; Zonnenberg BA Lancet Oncol; 2012 Oct; 13(10):1025-34. PubMed ID: 22920685 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]